Safety of
olokizumab
- The safety of Artlegia was evaluated in randomized, controlled clinical trials CREDO 1, CREDO 2, and CREDO 3. A total of 2444 patients with moderate to severe rheumatoid arthritis participated in the studies.
The immunogenicity potential of olokizumab according to the CREDO program is low and does not raise safety concerns
- A total of 2304 patients received OKZ every 2 week or every 4 week in combination with MTX. The overall exposure to olokizumab was 3625 patient-years with a mean treatment duration of 1.6 years (maximum 2.4). Exposure was 1839.5 PY with OKZ q2w and 1785.8 PY with OKZ q4w regimen.